Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells.
Stimulation of AMP-activated protein kinase (AMPK) in skeletal muscle has been correlated with an increase in glucose transport. Here, we demonstrate that adenoviral-mediated expression of a constitutively active mutant of AMPK alpha leads to activation of glucose transport in a skeletal-muscle cell line, similar to that seen following treatment with 5-amino-imidazolecarboxamide (AICA) riboside, hyperosmotic stress or insulin. In contrast, expression of a dominant-negative form of AMPK blocked the stimulation of glucose transport by both AICA riboside and hyperosmotic stress, but was without effect on either insulin or phorbol-ester-stimulated transport. These results demonstrate that activation of AMPK is sufficient for stimulation of glucose uptake into muscle cells, and is a necessary component of the AICA riboside- and hyperosmotic-stress-induced pathway leading to increased glucose uptake. On the other hand, AMPK is not required in the insulin- or phorbol-ester-mediated pathways. Long-term (5 days) expression of the constitutively active AMPK mutant increased protein expression of GLUT1, GLUT4 and hexokinase II, consistent with previous reports on the chronic treatment of rats with AICA riboside. Expression of constitutively active AMPK had no detectable effect on p38 mitogen-activated protein kinase levels, although interestingly the level of protein kinase B was decreased. These results demonstrate that long-term activation of AMPK is sufficient to cause increased expression of specific proteins in muscle. Our results add further support to the hypothesis that long-term activation of AMPK is involved in the adaptive response of muscle to exercise training.
Fryer
Lee G D
LG
Cellular Stress Group, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, DuCane Road London, W12 0NN, UK. lfryer@csc.mrc.ac.uk
Foufelle
Fabienne
F
Barnes
Kay
K
Baldwin
Stephen A
SA
Woods
Angela
A
Carling
David
D
D055372:AMP-Activated Protein Kinases; D000256:Adenoviridae / Q000235:genetics; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport; D015153:Blotting, Western; D002460:Cell Line; D003847:Deoxyglucose / Q000378:metabolism; D004789:Enzyme Activation; D005947:Glucose / Q000378:metabolism*; D006579:Heterozygote; D007328:Insulin / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009097:Multienzyme Complexes / Q000737:chemistry* / Q000502:physiology*; D018482:Muscle, Skeletal / Q000378:metabolism*; D009995:Osmosis; D010805:Physical Conditioning, Animal; D017346:Protein Serine-Threonine Kinases / Q000737:chemistry* / Q000502:physiology*; D012263:Ribonucleosides / Q000494:pharmacology
D007328:Insulin; D009097:Multienzyme Complexes; D012263:Ribonucleosides; D000620:Aminoimidazole Carboxamide; C011651:acadesine; D003847:Deoxyglucose; D017346:Protein Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases; D005947:Glucose